KOSDAQBiotech & Pharma096530

Seegene

₩36,800▼ 1.34%2026-10-02 close

Market Cap

₩1.7T

Turnover

₩8.9B

Volume

240,000 shares

Shares out.

46.7M

PER

—

PBR

—

EPS

—

Dividend Yield

3.13%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-10-02 close

Report overview

Non-Respiratory Testing Drives the Profit Recovery

After two loss-making years following the end of the COVID-19 boom, Seegene returned to an operating profit in 2025 and extended top-line and margin improvement through the first half of 2026 on non-respiratory testing (HPV, STI and gastrointestinal), leaving the pace of syndromic-test standardization and the commercialization of its automation and data platforms as the next things to watch.

1
2025 revenue of KRW 474.2bn and operating profit of KRW 34.5bn ended two consecutive years of operating losses, and operating profit of KRW 23.6bn in 1Q26 and KRW 21.6bn in 2Q26 kept the operating margin in double digits for two straight quarters.
2
The growth engine is the non-respiratory portfolio: in 2Q26 non-respiratory revenue rose 22.9% year on year, with HPV up 40.3%, STI up 20.7% and gastrointestinal up 13.9% (company release, 7 August 2026).
3
By region, Europe accounted for 57.2% of 2Q26 revenue, a high concentration, followed by Asia at 19.1%, Latin America at 12.4%, Korea at 6.4% and North America at 4.9% (company release).
4
The balance sheet is unlevered, with a 21.7% debt-to-equity ratio in 2025 and total equity of KRW 1,015.8bn, while 2025 operating cash flow of KRW 149.3bn far exceeded that year's operating profit.
5
Shareholder returns combine quarterly dividends with treasury share cancellation: in a 12 August 2026 filing the company said it would cancel 5,491,592 treasury shares, or 10.5% of shares issued and worth about KRW 173.7bn, on the 31st of that month.

Business structure

Seegene develops and manufactures multiplex (syndromic) real-time PCR assays that detect many pathogens in a single test, and pairs them with automation instruments covering extraction, dispensing and readout plus analysis software.

Recurring reagent sales sit at the centre of earnings, so the installed instrument base and test volume per instrument are the key operating metrics.

The portfolio splits broadly into respiratory products, whose demand clusters in winter, and less seasonal non-respiratory products spanning human papillomavirus (HPV), sexually transmitted infections (STI) and gastrointestinal (GI) testing, with antimicrobial resistance and hospital-acquired infection now added.

In May 2026 the company launched the Allplex MDRO Assay in Europe, widening its antibiotic-resistance diagnostics line-up. In 2Q26 revenue by region was Europe 57.2%, Asia 19.1%, Latin America 12.4%, Korea 6.4% and North America 4.9%, an overwhelming European tilt.

Sales run through a mix of local subsidiaries and distributors, and a French entity was established in December 2025 to reinforce the European commercial network.

In North America, subsidiary Seegene USA obtained a US FDA Emergency Use Authorization in July 2026 for the Allplex HSV-1&2/VZV/MPXV Assay, which detects herpes simplex 1 and 2, varicella zoster and monkeypox virus in one run.

On competition, a June 2025 Mirae Asset Securities field report from Europe noted that large assay markets such as HIV, HBV and HCV are held by global majors including Roche, Siemens and Abbott, and that HPV and chlamydia/gonorrhoea screening markets favour high-throughput instruments because unit price and automation matter most.

Seegene's differentiation lies in multiplexing that broadens test coverage in a single run, and in the technology-sharing and data-platform strategies built on it.

Earnings trend

Quarterly revenue · Operating profit

₩114.1B₩3.1B25Q2₩113.5B₩9.6B25Q3₩130.6B₩6.9B25Q4₩129.1B₩23.6B26Q1₩136B₩21.6B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩853.6B₩196.5B2022₩367.4B-₩30.1B2023₩414.3B-₩16.5B2024₩474.2B₩34.5B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩114.1B	₩3.1B	2.8%
2025Q3	₩113.5B	₩9.6B	8.5%
2025Q4	₩130.6B	₩6.9B	5.3%
2026Q1	₩129.1B	₩23.6B	18.2%
2026Q2	₩136B	₩21.6B	15.9%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩853.6B	₩196.5B	₩182.1B	23.0%	15.9%	20.9%
2023	₩367.4B	-₩30.1B	₩700M	−8.2%	0.1%	21.5%
2024	₩414.3B	-₩16.5B	-₩20.3B	−4.0%	−2.1%	22.8%
2025	₩474.2B	₩34.5B	₩48.3B	7.3%	4.8%	21.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

The starting point is the disappearance of the pandemic windfall.

From 2022 revenue of KRW 853.6bn and operating profit of KRW 196.5bn (a 23.0% operating margin), revenue collapsed to KRW 367.4bn in 2023 with an operating loss of KRW 30.1bn, and 2024 stayed in the red with revenue of KRW 414.3bn and an operating loss of KRW 16.5bn.

In 2025 revenue reached KRW 474.2bn, up roughly 14%, with operating profit of KRW 34.5bn (a 7.3% margin) and net profit attributable to owners of KRW 48.3bn, restoring profitability at the operating line.

Quarterly, the path ran from 2Q25 revenue of KRW 114.1bn with operating profit of KRW 3.1bn and a KRW 0.1bn net loss to owners, through KRW 113.5bn and KRW 9.6bn in 3Q25 and KRW 130.6bn and KRW 6.9bn in 4Q25, to 1Q26 revenue of KRW 129.1bn with operating profit of KRW 23.6bn (an 18.2% margin) and 2Q26 revenue of KRW 136.0bn with operating profit of KRW 21.6bn (15.9%) - a clear step up in margin level.

First-half 2026 totals were revenue of KRW 265.1bn, operating profit of KRW 45.1bn and net profit to owners of KRW 60.7bn.

Management attributed the first-quarter improvement to a 32.6% rise in non-respiratory syndromic sales, HPV tender wins and wider entry into screening markets, demand shifting to PCR, and better cost structure and expense control.

That said, Daol Investment & Securities wrote in a July 2026 report that the first quarter included one-off items such as a reversal of equipment valuation losses, with that effect fading in the second quarter, so the 1Q26 margin should not be read as a steady-state level.

Repeated quarters in which net profit exceeded operating profit point to sizeable non-operating contributions such as interest income from a net-cash balance sheet and foreign-exchange items, which makes quarterly net income more volatile than operating profit.

Cash generation has been firmer than reported earnings, with operating cash flow of KRW 149.3bn in 2025 versus KRW 85.4bn in 2024 and KRW 94.9bn in 2023, and at end-2025 total equity stood at KRW 1,015.8bn against total liabilities of KRW 220.0bn, a 21.7% debt-to-equity ratio.

Industry analysis

Molecular diagnostics is one of the faster-growing pillars inside in-vitro diagnostics (IVD).

Fortune Business Insights estimated the molecular diagnostics segment at about 30.5% of the IVD market in 2026, while Mordor Intelligence projected the molecular diagnostics market to grow from USD 19.68bn in 2026 to USD 31.24bn in 2031, a 10.4% compound annual rate.

By application, infectious disease was the largest area at 60.6% of 2025 revenue, which is also Seegene's core. Structural demand drivers include the shift of cervical cancer screening to HPV primary testing and the spread of self-collection.

The US FDA cleared self-collected vaginal samples for Roche and BD HPV tests in healthcare settings in 2024, and in Korea the Ministry of Food and Drug Safety has been working to create a self-test IVD product category covering sexually transmitted infections, raising the prospect of higher total test volumes as screening positives flow into confirmatory PCR.

Regulation cuts both ways, however. The European Union's IVDR tightens post-market surveillance, squeezing smaller manufacturers' margins while concentrating demand on integrated platforms. Competitive power still sits with the majors.

Mordor Intelligence describes the IVD market as somewhat consolidated around the top five suppliers - Roche, Abbott, Siemens Healthineers, Danaher and Thermo Fisher.

In HPV testing specifically, product competition continues, with Hologic's Aptima HPV Assay receiving FDA approval in February 2026 for clinician-collected primary screening, so Seegene's position hinges on its niche strategy of widening test coverage through multiplexing and on winning national screening volumes.

Outlook

Management's stated direction is non-respiratory-led growth alongside data and automation platforms.

In its 2026 corporate value-up plan Seegene listed non-respiratory-centred growth, expansion of overseas subsidiaries and distributor networks, entry into new markets, and the build-out of a test-data platform and automated testing systems as its main tasks.

The Global Million Clinical Study (GMCS), announced on 8 July, runs from August 2026 across countries including Korea and aims to accumulate one million real-world clinical test results to validate the clinical utility of syndromic PCR-based testing strategies and build the scientific basis for a new global testing standard.

On platforms, the STAgora test-data analytics platform and the CURECA unmanned PCR automation system were shown at ESCMID Global in April 2026, and upgraded models were presented at ADLM 2026 in the United States in July.

The company said it would focus on rolling out STAgora in the main countries where it has subsidiaries while accelerating readiness for CURECA's commercialization.

Monetization, though, still lies ahead: Daol Investment & Securities wrote in a May 2026 report that pilot services for new businesses such as STAgora and CURECA would begin in the second half, with commercialization only after 2027.

On near-term earnings, Daol Investment & Securities said in a 10 August 2026 report that HPV sales growth should continue on the two-to-three-year rescreening cycle tied to national screening programmes in Colombia and Brazil, estimated third-quarter revenue of KRW 133.1bn and operating profit of KRW 18.4bn, and raised its target price to KRW 47,000.

On shareholder returns, a 12 August 2026 filing set the cancellation of 5,491,592 treasury shares - 10.5% of shares issued, worth about KRW 173.7bn - for 31 August, alongside a quarterly cash dividend decision.

Valuation

PER

—

PBR

—

ROE

7.9%

EPS

—

BPS

—

Dividend per share

₩1,000

Any read on valuation has to start from the fact that the earnings base itself has changed sharply.

Operating losses in 2023 and 2024 made earnings-based multiples meaningless, and only after the 2025 return to profit and double-digit operating margins in the first half of 2026 has earnings-based comparison become possible at all.

Relative to book value the shares trade at a modest premium to net assets, and it is worth noting that price-to-book calculated in-house differs somewhat from the exchange-published figure because of how treasury shares are treated.

Earnings multiples cannot sensibly be compared with the pandemic boom years; instead the base earnings may be reset depending on how far rising non-respiratory weight damps seasonality and how quickly new-business spending is deployed.

Dividends are now paid quarterly, and the cancellation of more than 10% of shares issued means the real scale of shareholder returns is larger than a cash-dividend-only metric would capture.

At the same time, interest and foreign-exchange items contribute meaningfully to net profit, so an earnings multiple alone is a weak basis for judging the value of the operating business.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Less seasonality as the non-respiratory axis builds

Although 2Q26 was a seasonal trough for respiratory products, the non-respiratory portfolio of HPV, STI and gastrointestinal tests grew 22.9% year on year and carried the quarter. In the first quarter non-respiratory revenue rose 32.6%, with gastrointestinal, HPV and STI each up more than 30%.

With respiratory demand concentrated in winter, a larger share of year-round products narrows the swing in quarterly results. The change is visible in the off-season quarter itself: operating profit went from KRW 3.1bn in 2Q25 to KRW 21.6bn in 2Q26.

Near debt-free balance sheet and cash generation

At end-2025 total equity was KRW 1,015.8bn against total liabilities of KRW 220.0bn, a debt-to-equity ratio of just 21.7%. Operating cash flow of KRW 149.3bn in 2025 far exceeded that year's KRW 34.5bn operating profit, and cash still flowed in during the loss-making years of 2023 (KRW 94.9bn) and 2024 (KRW 85.4bn).

That reflects the heavy depreciation load of an instrument-based business, and it means R&D and new-business investment can be funded internally even when reported profit wobbles. The same structure is what allows quarterly dividends and a large treasury-share cancellation to run in parallel.

National screening inclusion and new product lines

The company cited HPV tender wins, wider entry into screening markets and demand shifting toward PCR-based testing as growth drivers.

Daol Investment & Securities said in its 10 August 2026 report that volumes tied to national screening programmes in Colombia and Brazil carry rescreening demand on a two-to-three-year cycle.

On products, a multidrug-resistant organism assay was launched in Europe in May 2026, and in July subsidiary Seegene USA secured a US FDA Emergency Use Authorization. Screening volumes are more repeatable than one-off orders, which changes the character of the revenue base.

Bear factors

Durability of the profit level is unproven

The 18.2% operating margin in 1Q26 should be read alongside Daol Investment & Securities' July 2026 analysis that one-off items such as a reversal of equipment valuation losses were included and that the fading of that effect would push second-quarter operating profit below the first quarter.

Indeed, 2Q26 operating profit of KRW 21.6bn came in below 1Q26's KRW 23.6bn. Quarters such as 1Q26, with net profit to owners of KRW 34.7bn well above operating profit, also show non-trivial dependence on non-operating items. On a full-year basis, the 2025 operating margin of 7.3% is still short of double digits.

European concentration and pressure from global majors

Europe generated 57.2% of 2Q26 revenue while North America accounted for only 4.9%. That means changes in one region's screening policy, reimbursement or currency pass straight through to group results.

Mirae Asset Securities argued in a June 2025 report that HPV and chlamydia/gonorrhoea screening markets favour global majors' high-throughput instruments because unit price and automation dominate, and that competitors unable to multiplex can still book more revenue by billing per target.

Market researchers also describe the IVD market as consolidated around its top five suppliers. In large screening tenders, pricing power often sits with the buyer.

Uncertain timing for new-business monetization

STAgora, CURECA and GMCS are all medium-to-long-term projects with no confirmed revenue contribution today. Daol Investment & Securities wrote in May 2026 that pilot services would start in the second half but commercialization would come only after 2027.

The same house wrote in July 2026 that CURECA and STAgora were still at the stage of exploring practical deployment. A million-test clinical study has a clear rationale as data-asset accumulation, but research, software and personnel costs are spent up front regardless of the outcome.

Risk factors

Demand volatility and seasonality

Respiratory testing volumes swing with the severity of each winter season, and the gap between operating profit of KRW 3.1bn in 2Q25 and KRW 23.6bn in 1Q26 illustrates that volatility. In a mild season, expectations for the fourth and first quarters can be cut quickly.

A rising non-respiratory share cushions this, but screening volumes such as HPV can also cluster by quarter depending on national programme schedules. The post-pandemic demand base is still in a proving period.

Regulation and approvals

The European Union's IVDR tightens post-market surveillance, raising the cost of maintaining certification. Analysts also note that Europe's strict enforcement of IVD rules lengthens approval timelines and favours multinationals with experienced regulatory teams.

With more than half of revenue coming from Europe, certification delays or changed requirements feed directly into supply. In the United States, emergency use authorization and full clearance carry different requirements, so the pace of North American expansion depends on the regulatory path.

Costs and capital allocation

Data platforms and unmanned automation carry fixed-cost-like spending on software and personnel, so a delayed revenue contribution would narrow the scope for operating-margin improvement.

At the same time, quarterly dividends and the cancellation of treasury shares equal to 10.5% of shares issued, worth about KRW 173.7bn, reduce cash holdings. If allocation tilts too far toward either growth investment or shareholder returns, expectations for the other will be reset.

Intangible assets and valuation gains or losses arising from overseas entities and acquired businesses are further sources of earnings variability.

What to watch next

Early November 2026
Third-quarter 2026 preliminary results. The key questions are whether non-respiratory double-digit growth persists and whether the operating margin holds near first-half levels as the respiratory season begins. Daol Investment & Securities estimated third-quarter revenue of KRW 133.1bn and operating profit of KRW 18.4bn in its 10 August 2026 report.
September to December 2026
The pace at which revenue is recognized from the multidrug-resistant organism assay launched in Europe in May 2026. Daol Investment & Securities wrote in July 2026 that an Italian contract had been secured before launch but that second-quarter revenue recognition was still limited. This is the window to see whether hospital-acquired infection and antimicrobial resistance become a third growth pillar.
Fourth quarter 2026
The actual start and progress of STAgora and CURECA pilot services. Daol Investment & Securities wrote in May 2026 that pilots would begin in the second half with commercialization after 2027. Which countries and laboratories adopt them, and how they are charged, will be the first read on whether the new businesses can be monetized.
December 2026 to March 2027
Year-end dividend and any further shareholder-return decisions, plus audited full-year 2026 results. Watch how remaining treasury shares are handled after the August cancellation, whether the dividend policy is sustained, and how far the 2026 full-year operating margin rises from 7.3% in 2025.
First half of 2027
Initial data disclosure and conference presentations from the Global Million Clinical Study (GMCS) that began in August 2026. The company said it would gather clinical results for combined HPV and STI testing through GMCS and statistically validate clinical utility using STAgora. Whether those findings feed into screening guidelines or national tender specifications bears directly on the medium-term revenue structure.

Overall view

The past two years at Seegene have been about absorbing the end of the pandemic windfall.

From 2022 revenue of KRW 853.6bn and operating profit of KRW 196.5bn, the company slid to operating losses of KRW 30.1bn in 2023 and KRW 16.5bn in 2024, then returned to profit in 2025 with revenue of KRW 474.2bn and operating profit of KRW 34.5bn, and posted first-half 2026 revenue of KRW 265.1bn with operating profit of KRW 45.1bn, a clear step up in margin level.

The content of the improvement is clear: less seasonal non-respiratory products spanning HPV, STI and gastrointestinal testing grew 22.9% in 2Q26 and filled the respiratory off-season.

On the other side sit a 57.2% revenue concentration in Europe, an IVD competitive structure led by the top five suppliers, and new ventures such as STAgora, CURECA and GMCS where spending comes first and monetization later.

The balance sheet has room, with a 21.7% debt-to-equity ratio and 2025 operating cash flow of KRW 149.3bn, and the company has paired quarterly dividends with the cancellation of treasury shares equal to 10.5% of shares issued.

What remains to be verified boils down to two things: whether non-respiratory growth and double-digit operating margins hold across seasons, and whether the data and automation platforms move from the cost line to the revenue line. This report is for information purposes only and contains no investment recommendation or buy or sell opinion.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.